Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology.

Negash S, Xie S, Davatzikos C, Clark CM, Trojanowski JQ, Shaw LM, Wolk DA, Arnold SE.

Alzheimers Dement. 2013 May;9(3):e89-95. doi: 10.1016/j.jalz.2012.01.009.

2.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
3.

Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.

Roe CM, Fagan AM, Grant EA, Marcus DS, Benzinger TL, Mintun MA, Holtzman DM, Morris JC.

Arch Neurol. 2011 Sep;68(9):1145-51. doi: 10.1001/archneurol.2011.192.

4.

Brain size and the compensation of Alzheimer's disease symptoms: a longitudinal cohort study.

Guo LH, Alexopoulos P, Wagenpfeil S, Kurz A, Perneczky R; Alzheimer's Disease Neuroimaging Initiative..

Alzheimers Dement. 2013 Sep;9(5):580-6. doi: 10.1016/j.jalz.2012.10.002.

PMID:
23232272
5.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
6.

The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases.

Murray AD, Staff RT, McNeil CJ, Salarirad S, Ahearn TS, Mustafa N, Whalley LJ.

Brain. 2011 Dec;134(Pt 12):3687-96. doi: 10.1093/brain/awr259.

PMID:
22102649
7.

Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia.

Mesulam M, Wicklund A, Johnson N, Rogalski E, Léger GC, Rademaker A, Weintraub S, Bigio EH.

Ann Neurol. 2008 Jun;63(6):709-19. doi: 10.1002/ana.21388.

8.

Cognitive reserve, presynaptic proteins and dementia in the elderly.

Honer WG, Barr AM, Sawada K, Thornton AE, Morris MC, Leurgans SE, Schneider JA, Bennett DA.

Transl Psychiatry. 2012 May 15;2:e114. doi: 10.1038/tp.2012.38.

9.

Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.

Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM.

JAMA Neurol. 2015 Jun;72(6):656-65. doi: 10.1001/jamaneurol.2015.0202.

10.

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM.

Lancet Neurol. 2013 Oct;12(10):957-65. doi: 10.1016/S1474-4422(13)70194-7.

11.

Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes.

Hohman TJ, Samuels LR, Liu D, Gifford KA, Mukherjee S, Benson EM, Abel T, Ruberg FL, Jefferson AL; Alzheimer's Neuroimaging Initiative..

Neurobiol Aging. 2015 Sep;36(9):2501-8. doi: 10.1016/j.neurobiolaging.2015.05.021.

12.

Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum.

Solé-Padullés C, Lladó A, Bartrés-Faz D, Fortea J, Sánchez-Valle R, Bosch B, Antonell A, Molinuevo JL, Rami L.

Psychiatry Res. 2011 Jun 30;192(3):140-6. doi: 10.1016/j.pscychresns.2010.12.001.

PMID:
21546220
13.

Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.

Huded CB, Bharath S, Chandra SR, Sivakumar PT, Varghese M, Subramanian S.

Asian J Psychiatr. 2015 Feb;13:44-7. doi: 10.1016/j.ajp.2014.10.007.

PMID:
25468261
14.

Relationship of dementia screening tests with biomarkers of Alzheimer's disease.

Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC.

Brain. 2010 Nov;133(11):3290-300. doi: 10.1093/brain/awq204.

15.

Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers.

Binnewijzend MA, Adriaanse SM, Van der Flier WM, Teunissen CE, de Munck JC, Stam CJ, Scheltens P, van Berckel BN, Barkhof F, Wink AM.

Hum Brain Mapp. 2014 May;35(5):2383-93. doi: 10.1002/hbm.22335.

PMID:
24039033
16.

CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.

Baumann TP, Duyar H, Sollberger M, Kuhle J, Regeniter A, Gomez-Mancilla B, Schmidtke K, Monsch AU.

Dement Geriatr Cogn Disord. 2010;29(6):530-3. doi: 10.1159/000314679.

PMID:
20606434
17.

Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.

Martiskainen H, Helisalmi S, Viswanathan J, Kurki M, Hall A, Herukka SK, Sarajärvi T, Natunen T, Kurkinen KM, Huovinen J, Mäkinen P, Laitinen M, Koivisto AM, Mattila KM, Lehtimäki T, Remes AM, Leinonen V, Haapasalo A, Soininen H, Hiltunen M.

J Alzheimers Dis. 2015;43(2):565-73. doi: 10.3233/JAD-140777.

PMID:
25096612
18.

Effect of cognitive reserve markers on Alzheimer pathologic progression.

Lo RY, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative..

Alzheimer Dis Assoc Disord. 2013 Oct-Dec;27(4):343-50. doi: 10.1097/WAD.0b013e3182900b2b.

19.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
20.

Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.

Thordardottir S, Ståhlbom AK, Ferreira D, Almkvist O, Westman E, Zetterberg H, Eriksdotter M, Blennow K, Graff C.

J Alzheimers Dis. 2015;43(4):1393-402. doi: 10.3233/JAD-140339.

PMID:
25182737
Items per page

Supplemental Content

Support Center